TY - JOUR
T1 - ESCMID guideline for the diagnosis and management of Candida diseases 2012
T2 - developing European guidelines in clinical microbiology and infectious diseases
AU - Ullmann, A.J.
AU - Cornely, O.A.
AU - Donnelly, J.P.
AU - Akova, M.
AU - Arendrup, M.
AU - Arikan-Akdagli, S.
AU - Bassetti, M.
AU - Bille, J.
AU - Calandra, T.
AU - Castagnola, E.
AU - Garbino, J.
AU - Groll, A.H.
AU - Herbrecht, R.
AU - Hope, W.W.
AU - Jensen, Henrik Elvang
AU - Kullberg, B.J.
AU - Lass-Flörl, C.
AU - Lortholary, O.
AU - Meersseman, W.
AU - Petrikkos, G.
AU - Richardson, M.
AU - Roilides, E.
AU - Verweij, P.E.
AU - Viscoli, C.
AU - Cuenca-Estrella, M.
PY - 2012/12
Y1 - 2012/12
N2 - The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) successfully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID task force (basically composed of members of the Society's Fungal Infection Study Group, EFISG) finalized the ESCMID diagnostic and management/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups were predefined, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplantation. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical intervention, which was graded by a score of A-D for the 'Strength of a recommendation'. The 'level of evidence' received a score of I-III. The author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guidelines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.
AB - The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) successfully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID task force (basically composed of members of the Society's Fungal Infection Study Group, EFISG) finalized the ESCMID diagnostic and management/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups were predefined, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplantation. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical intervention, which was graded by a score of A-D for the 'Strength of a recommendation'. The 'level of evidence' received a score of I-III. The author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guidelines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.
U2 - 10.1111/1469-0691.12037
DO - 10.1111/1469-0691.12037
M3 - Journal article
C2 - 23137133
SN - 1198-743X
VL - 18
SP - 1
EP - 8
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - Suppl. s7
ER -
